Description
MEXAPAN-LSR combines Pantoprazole Sodium equivalent to Pantoprazole 40 mg with Levosulpiride 75 mg in a sustained-release formulation. Pantoprazole reduces gastric acid production, while Levosulpiride supports gastrointestinal motility. Therefore, healthcare professionals may prescribe this combination for short-term management of gastroesophageal reflux disease (GERD) in adults who do not respond adequately to a proton pump inhibitor alone.
For related gastrointestinal formulations and other pharmaceutical products, explore the Medhexa Pharma product range.
Therapeutic Segment
Gastrointestinal Care | GERD Management | Acid-Related Disorders | Proton Pump Inhibitors | Prokinetic Therapy
Uses of MEXAPAN-LSR
MEXAPAN-LSR may support the short-term treatment of gastroesophageal reflux disease (GERD) in adults who do not achieve adequate symptom control with a proton pump inhibitor alone. The combination brings together Pantoprazole’s acid-suppressing action and Levosulpiride’s gastrointestinal motility support.
Potential clinical uses include:
- Gastroesophageal reflux disease (GERD)
- Acid reflux and associated heartburn
- Acid-related upper gastrointestinal symptoms
- GERD in adults who do not respond adequately to PPI therapy alone
- Selected gastrointestinal symptoms where a healthcare professional considers the combination appropriate
However, the healthcare professional should determine the exact indication according to the patient’s condition and approved product information.
Key Benefits of MEXAPAN-LSR
MEXAPAN-LSR provides complementary gastrointestinal actions through its two active ingredients.
- Pantoprazole 40 mg reduces gastric acid secretion.
- Levosulpiride 75 mg SR supports gastrointestinal motility.
- The combination addresses acid-related symptoms alongside selected gastrointestinal motility symptoms.
- The sustained-release formulation provides modified release of Levosulpiride.
- The capsule dosage form allows convenient oral administration.
- The product comes in 10 × 10 ALU-ALU packaging.
Moreover, CDSCO specifically records this combination for short-term GERD treatment in adult patients who do not respond adequately to PPI therapy alone.
How MEXAPAN-LSR Works
First, Pantoprazole acts as a proton pump inhibitor. It blocks the H⁺/K⁺-ATPase proton pump in gastric parietal cells. As a result, the stomach produces less acid. This action helps reduce acid exposure and supports symptom control in acid-related gastrointestinal conditions.
Meanwhile, Levosulpiride acts primarily through dopamine receptor antagonism and supports gastrointestinal motility. This action can help promote gastric movement and improve the passage of gastrointestinal contents.
Thus, MEXAPAN-LSR combines gastric acid suppression with gastrointestinal motility support.
Common Side Effects of MEXAPAN-LSR
Some patients may experience side effects while taking Pantoprazole or Levosulpiride. Possible effects can include:
- Headache
- Nausea
- Diarrhea
- Constipation
- Abdominal discomfort
- Dry mouth
- Dizziness
- Fatigue
- Restlessness
In addition, Levosulpiride may cause movement-related or hormonal effects in some patients because of its dopamine-blocking activity.
However, side effects vary from person to person. Contact a healthcare professional if symptoms persist, become severe or interfere with normal activities.
Important Safety Information
Use MEXAPAN-LSR only under the guidance of a qualified healthcare professional.
Before starting treatment, inform your healthcare professional about any history of seizures, movement disorders, gastrointestinal bleeding, intestinal obstruction or other significant gastrointestinal conditions.
Levosulpiride can cause neurological or hormonal adverse effects in some patients. Therefore, report unusual muscle movements, tremors, stiffness, severe restlessness or other abnormal neurological symptoms to your healthcare professional.
Furthermore, tell your healthcare professional about all medicines you currently take. Levosulpiride can interact with medicines that affect the central nervous system or dopamine pathways.
Pantoprazole can also interact with certain medicines. For example, healthcare professionals need to consider medicines whose absorption depends on gastric acidity, as well as specific drugs such as rilpivirine-containing products.
Long-term PPI therapy can also involve additional risks, including hypomagnesemia, vitamin B12 deficiency and certain bone-related risks. Therefore, healthcare professionals should review prolonged Pantoprazole treatment periodically.
Patients with liver disease should inform their healthcare professional before starting treatment. Pregnant or breastfeeding patients should also seek medical advice before using MEXAPAN-LSR.
Dosage & Administration
Take MEXAPAN-LSR exactly as prescribed by your healthcare professional. The appropriate dose and treatment duration depend on the patient’s condition and response to treatment.
Pantoprazole generally works best when taken before a meal. Swallow the capsule whole with water and follow the specific instructions provided with the product.
Because MEXAPAN-LSR contains Levosulpiride 75 mg SR, do not crush, chew or alter the sustained-release dosage form unless the approved product information specifically permits another method.
Do not increase the dose, extend treatment or combine MEXAPAN-LSR with another Levosulpiride-containing medicine without medical advice.
Moreover, this combination has a specific short-term GERD indication in adults who do not respond adequately to PPI therapy alone. Therefore, follow the treatment duration recommended by the prescribing healthcare professional.
Storage
Store MEXAPAN-LSR in a cool, dry place away from excessive heat, moisture and direct sunlight.
Keep the capsules in their original ALU-ALU packaging until use. Also, keep the medicine out of reach of children.
Follow the specific storage conditions printed on the product packaging.
